{"id":"high-dose-colistin","safety":{"commonSideEffects":[{"rate":"20-50","effect":"Nephrotoxicity (acute kidney injury)"},{"rate":"7-25","effect":"Neurotoxicity (paresthesias, dizziness, vertigo)"},{"rate":null,"effect":"Neuromuscular blockade"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Colistin acts as a cationic antimicrobial peptide that interacts with the outer membrane of gram-negative bacteria, particularly lipopolysaccharides (LPS), leading to membrane destabilization and cell death. High-dose formulations are used to achieve adequate concentrations for treating serious infections caused by multidrug-resistant gram-negative organisms, especially Pseudomonas aeruginosa and Acinetobacter baumannii. The drug is typically reserved for infections resistant to other antibiotics due to its nephrotoxicity and neurotoxicity profile.","oneSentence":"Colistin is a polymyxin antibiotic that disrupts bacterial cell membranes by binding to lipopolysaccharides and causing leakage of cellular contents.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:48.742Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multidrug-resistant gram-negative bacterial infections (Pseudomonas aeruginosa, Acinetobacter baumannii)"},{"name":"Hospital-acquired pneumonia caused by resistant gram-negative organisms"},{"name":"Bloodstream infections caused by multidrug-resistant gram-negative bacteria"}]},"trialDetails":[{"nctId":"NCT07326540","phase":"PHASE3","title":"Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","status":"NOT_YET_RECRUITING","sponsor":"BioVersys SAS","startDate":"2026-03-20","conditions":"Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP), Colistin Resistanrt ABC","enrollment":248},{"nctId":"NCT06472271","phase":"","title":"Colistin Dosage Prsonalization Approach","status":"RECRUITING","sponsor":"Mahmoud I Mostafa","startDate":"2024-07-30","conditions":"Colistin Adverse Reaction","enrollment":100},{"nctId":"NCT07004049","phase":"PHASE4","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-04-21","conditions":"Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia","enrollment":600},{"nctId":"NCT02472600","phase":"PHASE2","title":"Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy","status":"UNKNOWN","sponsor":"Stephen Harbarth","startDate":"2016-02","conditions":"Intestinal Colonization With Multidrug-resistant Bacteria","enrollment":39},{"nctId":"NCT02162966","phase":"PHASE4","title":"Safety and Efficacy Study of High Dose Colistin","status":"UNKNOWN","sponsor":"King Saud Medical City","startDate":"2014-05","conditions":"Infectious Diseases","enrollment":330}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["colistin"],"phase":"marketed","status":"active","brandName":"High Dose Colistin","genericName":"High Dose Colistin","companyName":"King Saud Medical City","companyId":"king-saud-medical-city","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Colistin is a polymyxin antibiotic that disrupts bacterial cell membranes by binding to lipopolysaccharides and causing leakage of cellular contents. Used for Multidrug-resistant gram-negative bacterial infections (Pseudomonas aeruginosa, Acinetobacter baumannii), Hospital-acquired pneumonia caused by resistant gram-negative organisms, Bloodstream infections caused by multidrug-resistant gram-negative bacteria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}